NT-proBNP is a cornerstone biomarker in the diagnosis and management of heart failure. Despite its widespread use, important biological and analytical challenges remain. One of the most sign ...

LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited, a next-generation point of care diagnostics company, today announced it has commenced commercial shipment of its point of care NT-proBNP ...

In people with no history of CV disease, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels can predict a higher risk of developing CV disease across various blood pressure and pulse pressure ...

Zomedica launches two canine assays for TRUFORMA, including NT-proBNP for heart disease and progesterone for breeding. The assays provide reference lab-level accuracy in-clinic, enhancing diagnostics ...

Patients who underwent invasive hemodynamic testing—at rest and while exercising—at Mayo Clinic Rochester’s catheterization laboratory between February 2006 and March 2018 who had both recorded ...

At this year's congress of the American Heart Association (AHA) in Chicago, November 13-17, new data on the use of NT-proBNP to guide heart failure therapy was presented by study investigators from ...

Dallas, TX - The addition of natriuretic peptide testing to the traditional clinical evaluation of patients with dyspnea of suspected cardiac origin cut the duration of emergency-department visits by ...

"HF algorithms are starting to recognize and include NT-proBNP in identifying stage B HF…Studies such as ours could provide insight and guidance as to when repeat measures may be useful. Future work ...

Patent ductus arteriosus (PDA) is common in preterm infants and is associated with significant morbidities. B type natriuretic peptide (BNP) is synthesized in the ventricles secondary to volume ...

In this new subanalysis of data from the Atherosclerosis Risk in the Communities study, investigators assessed the risk of incident heart failure (HF) or death by race and sex, as influenced by ...